In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease.
Gisa, Steffi, and César join TWiV to discuss their careers, their research, and the COVID-19 pandemic in Germany.
The TWiVers review Biden’s national strategy for COVID-19 responses and pandemic preparedness, and an evaluation of the BinaxNOW rapid antigen test for SARS-CoV-2 infection.
In COVID-19 clinical update #46, Daniel Griffin discusses the BinaxNow rapid antigen test, efficacy of Bamlanivimab in nursing homes, associations of serum vitamin D concentrations with in-hospital mortality and need for invasive mechanical ventilation, trials of IL-6 receptor antagonists, effects of anticoagulants on in-hospital mortality, and symptom persistence in outpatients.
In this episode, President Biden elevates his science advisor to his Cabinet, a review of the current flu season, the scientific goals of the WHO-convened Global Study of the Origins of SARS-CoV-2, and answers to listener questions.
The TWiVy team deconstructs CoronaVac, the inactivated SARS-CoV-2 vaccine produced by Sinovac Biotech, and production of multivalent camelid nanobodies that block infection with the virus and suppress selection of neturalization-resistant variants.
In COVID-19 clinical update #45, Daniel Griffin discusses J&J Ad26 vaccine results, reactogenicity after the second dose of mRNA vaccines, expansion of vaccine eligibility, and the finding that encephalitis after SARS-CoV-2 infection is a cytokine release syndrome.
TWiV answers listener questions about pandemic response, excess deaths in 25-44 year olds, vaccines, vaccines, and vaccines.
Emily Travanty from the Colorado Department of Public Health and Environment joins TWiV to discuss how her laboratory was the first in the US to detect the SARS-CoV-2 variant VOC 202012/01.
In this COVID-19 clinical update, Daniel Griffin summarizes current status of vaccination in the US, discusses a study on convalescent sera from Argentina, use of remdesivir in patients with kidney disease, and provides further considerations on the use of Ct values in patient management.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.